

Manual of Antibiotics and Infectious Diseases


JOHN E. CONTE

STEVEN L. BARRIÈRE

Sixth Edition



一九九二年三月十六日



Manual of Antibiotics and Infectious Diseases

JOHN E. CONTE, JR., M.D.

Associate Clinical Professor of Medicine, Microbiology
and Clinical Pharmacy

Division of Infectious Diseases

Director, Hospital Infection Control Unit

University of California, San Francisco

STEVEN L. BARRIERE, Pharm. D.

Specialist in Infectious Diseases

Department of Pharmaceutical Services

Adjunct Associate Professor of Medicine

Division of Infectious Diseases

Department of Medicine

University of California, Los Angeles

Sixth Edition



LEA & FEBIGER



Philadelphia

Lea & Febiger
600 Washington Square
Philadelphia, PA 19106-4198
U.S.A.
(215) 922-1330

Library of Congress Cataloging in Publication Data

Conte, John E.

Manual of antibiotics and infectious diseases.

Includes bibliographies and index.

1. Antibiotics--Handbooks, manuals, etc.
2. Communicable diseases--Chemotherapy--Handbooks, manuals, etc. I. Barriere, Steven L. II. Title.

[DNLM: 1. Antibiotics--handbooks. 2. Communicable diseases--drug therapy--handbooks. QV 39 C761m].

RM267.C63 1987

615'.329

87-2988

ISBN 0-8121-1107-9

Copyright © 1988 by Lea & Febiger. Copyright under the International Copyright Union. All Rights Reserved. This book is protected by copyright. No part of it may be reproduced in any manner or by any means without written permission of the publisher.

PRINTED IN THE UNITED STATES OF AMERICA

Print No. 3 2

Preface

This manual is designed for students, housestaff, practicing physicians, and other health professionals involved in the day-to-day care of patients with infectious diseases. An attempt has been made to incorporate into one book a variety of important source materials that ordinarily can be found in many different locations:

The manual is divided into eight sections:

Section I. Antibiotics

Clinically important information is presented for each antibiotic. In some instances, two or three antibiotics that are similar are discussed together. This section includes the availability and trade names of each drug, its clinical use, administration and dosage, dosage in renal insufficiency, pharmacology, adverse reactions, and drug interactions. Further reading lists are also supplied.

Section II. Empiric Antibiotic Therapy

Recommendations are made for drugs of choice, alternative therapy, appropriate dosages, and routes of administration for various clinical situations in which infection is suspected.

Section III. Therapy of Established Infection

Empiric antibiotic therapy is continued until Gram stains and cultures from the laboratory reveal one or more specific agents. At this point, specific therapy is begun; this section summarizes antibiotic choices, doses, route of administration, and duration of therapy.

Section IV. Antibiotic Susceptibilities

Section V. Prophylactic Antibiotics

This section provides guidelines for the use of prophylactic antibiotics; general principles; American Heart Association recommendations for the prevention of endocarditis during various surgical procedures; American Heart Association recommendations for the

prevention of rheumatic fever; tuberculosis; and meningococcal infection.

Section VI. Availability and Clinical Use of Immunobiologic Agents and Antiparasitic Drugs

These agents are available by request from the Immunobiologics, Biologic Products Division, Bureau of Laboratories, of the Center for Disease Control. Guidelines are given for the use of BCG; immune serum globulin and hepatitis B immune globulin; influenza vaccine; pneumococcal vaccine; polio vaccine; rabies immune globulin; tetanus prophylaxis; immunobiologic agents and drugs distributed by the CDC and drugs for the treatment of parasitic infections, including malaria.

Section VII. Sexually Transmitted Diseases—Treatment Guidelines

United States Public Health Service recommendations for the treatment of syphilis and gonorrhea are provided.

San Francisco, California
Los Angeles, California

JOHN E. CONTE, JR.
STEVEN L. BARRIERE

Acknowledgments

We would like to dedicate this manual to our wives, Michelle and Joan, without whose patience and understanding this manual would not have been possible.

We would like to thank Karen Mah-Hing for her patient secretarial assistance.



Abbreviations

AIDS	acquired immunodeficiency syndrome
bid	twice a day
BUN	blood urea nitrogen
cc	cubic centimeter
CDC	Center for Disease Control
CNS	central nervous system
Cl _{CR}	creatinine clearance
C _p	plasma concentration
Cr _s	serum creatinine
CSF	cerebrospinal fluid
dl	deciliter(s)
FTA-ABS	fluorescent treponemal antibody absorption (test)
GI	gastrointestinal
g	gram(s)
G6PD	glucose-6-phosphate dehydrogenase (deficiency)
HIV	human immunodeficiency virus
hr	hour(s)
ID	intra dermal
IM	intramuscular
IT	intrathecal
IU	international unit(s)
IV	intravenous
kg	kilogram(s)
L	Liter
L.D	loading dose

LP	lumbar puncture
M	molar
MBC	minimum bactericidal concentration
mcg	microgram(s)
MD	maintenance dose
meq	milliequivalent
mg	milligram(s)
MIC	minimum inhibitory concentration
MLC	minimum lethal concentration
ml	milliliter(s)
MU	million units
PO	by mouth
PPD	purified protein derivative (of tuberculin)
qd	daily, once a day
qid	4 times a day
qod	every other day
q2h	every 2 hours
q4h	every 4 hours
q6h	every 6 hours
q8h	every 8 hours
q12h	every 12 hours
RBC	red blood cell
RPR	rapid protein reagin
SIADH	syndrome of inappropriate antidiuretic hormone secretion
$t_{1/2}$	half-life
TB	tuberculosis
TGC	third-generation cephalosporin
tid	3 times a day
U	unit(s)
UTI	urinary tract infection
V_d	volume of distribution
VDRL	Venereal Disease Research Laboratories

Contents

Section I. Antibiotics	1
Acyclovir	6
Amantadine	9
Amdinocillin	10
Amikacin	11
Amoxicillin	14
Amphotericin B (AmB)	15
Ampicillin	17
Azlocillin/Mezlocillin/Piperacillin	19
Aztreonam	20
Capreomycin	21
Carbenicillin	22
Cefaclor	23
Cefadroxil	23
Cefamandole	24
Cefazolin	25
Cefonicid/Ceforanide	26
Cefoperazone	27
Cefotaxime	28
Cefotetan	29
Cefoxitin	30
Ceftazidime	31
Ceftizoxime	32
Ceftriaxone	33
Cefuroxime	34
Cephalexin/Cephradine	34
Cephalothin/Cephapirin	35
Chloramphenicol	37
Cinoxacin	39
Clavulanic Acid	39
Clindamycin	41
Cloxacillin/Dicloxacillin	42

Colistin (Colistimethate)/Polymyxin B	43
Cycloserine	44
Doxycycline	45
Erythromycin	46
Ethambutol	47
Ethionamide	48
Flucytosine (5-Fluorocytosine)	49
Gentamicin	50
Griseofulvin	52
Imipenem-Cilastatin	53
Isoniazid	54
Kanamycin	56
Ketoconazole	57
Methenamine	58
Methicillin	59
Methisazone	60
Metronidazole	61
Miconazole	62
Minocycline	63
Moxalactam	64
Nafcillin	66
Nalidixic Acid	67
Netilmicin	68
Nitrofurantoin	69
Oxacillin	70
Para-Aminosalicylic Acid (PAS)	71
Penicillin G	72
Penicillin V (Phenoxymethyl Penicillin)	75
Pentamidine	76
Pyrazinamide	77
Primethamine	78
Quinolones	79
Rifampin	80
Spectinomycin	81
Streptomycin	82
Sulfadoxine	83
Sulfisoxazole	84
Tetracycline	86
Ticarcillin	88
Tobramycin	89
Trimethoprim and Sulfamethoxazole (Co-Trimoxazole)	90
Vancomycin	92
Vidarabine	94
Viomycin	94

Section II. Empiric Antibiotic Therapy	96
Table II-1. Empiric Antibiotic Therapy—Cardiovascular Infection	97
Table II-2. Empiric Antibiotic Therapy—Musculoskeletal Infection	98
Table II-3. Empiric Antibiotic Therapy—CNS Infection	99
Table II-4A. Empiric Antibiotic Therapy—Sexually Transmitted Diseases and Other Urogenital Infections—Gonorrhea	100
Table II-4B. Syphilis	101
Table II-4C. Chancroid and Lymphogranuloma Venereum ..	102
Table II-4D. Chlamydia Trachomatis Infection	102
Table II-4E. Syndromes Associated with Sexually Transmitted Diseases	103
Table II-5. Empiric Antibiotic Therapy—Gastrointestinal Infection	104
Table II-6. Empiric Antibiotic Therapy—Urinary Tract Infection	105
Table II-7. Empiric Antibiotic Therapy—Respiratory Infection	106
Table II-8. Empiric Antibiotic Therapy—Skin Infection	108
 Section III. Therapy of Established Infection	109
Table III-1. Infective Endocarditis	110
Table III-2. Musculoskeletal Infection	113
Table III-3. Pediatric Meningitis	115
Table III-3A. Adult Meningitis	117
Table III-4. Acute Bacterial Gastroenteritis	118
Table III-4A. Gastrointestinal Infection	120
Table III-5. Urinary Tract Infection	122
Table III-6. Respiratory Infection	124
Table III-7. Miscellaneous Infections	127
 Section IV. Antibiotic Susceptibilities	135
Table IV-1. Minimum Inhibitory Concentration Interpretive Standards (mcg/ml)—Three Categories of Susceptibility ..	136
Table IV-2. Minimum Inhibitory Concentrations for Susceptible Organisms (mcg/ml)—Gram-Positive Bacteria	140
Table IV-3. Minimum Inhibitory Concentrations for Susceptible Organisms (mcg/ml)—Gram-Negative Bacteria	142
Table IV-4. Comparable In-Vitro Activity of New Cephalosporin Agents Against Major Pathogens	144
Table IV-5. Antimicrobial Activity of the Fluoroquinolones ..	146

Table IV-6. Minimum Inhibitory Concentrations for Susceptible Organisms (mcg/ml)—Anaerobic Bacteria	148
Table IV-7. Minimum Inhibitory Concentrations for Susceptible Organisms (mcg/ml)—Miscellaneous Organisms	149
Table IV-8. Minimum Inhibitory Concentrations for Susceptible Organisms (mcg/ml)—Mycobacteria	150
Table IV-9. Runyon Classification of Atypical Mycobacteria ..	151
Section V. Prophylactic Antibiotics.	153
Surgical Prophylaxis	153
Medical Prophylaxis	153
Guidelines for Isoniazid Prophylaxis of Tuberculous Infection	165
Prevention of Rheumatic Fever	172
Guidelines for Meningococcal Prophylaxis	178
Prevention of Secondary Cases of <i>Haemophilus Influenzae</i> Type B Disease	180
Malaria Chemoprophylaxis (see Section VI—Clinical Use of Antiparasitic Drugs)	
Section VI. Availability and Clinical Use of Immunobiologic Agents and Antiparasitic Drugs	187
BCG Vaccine	187
Botulism Equine Antitoxin (ABE)	189
Diphtheria Equine Antitoxin	190
Diphtheria, Tetanus, and Pertussis	191
Influenza Vaccine	212
Measles Virus Vaccine	225
Mumps Vaccine	233
Pneumococcal Vaccine	238
Poliomyelitis Vaccines	243
Rabies Prevention	249
Vaccinia Immune Globulin (VIG)	261
Varicella-Zoster Immune Globulin (VZIG)	263
Immunobiologic Agents and Drugs Distributed by the Center for Disease Control	274
Clinical Use of Antiparasitic Drugs	304
Section VII. Sexually Transmitted Diseases—Treatment Guidelines.	327
Acquired Immunodeficiency Syndrome (AIDS)	327
Chancroid (<i>Haemophilus ducreyi</i>) Infection	329
<i>Chlamydia trachomatis</i> Infection	330
Enteric Infections	332

Gonococcal Infections	334
Viral Hepatitis	340
Genital Herpes Simplex Virus Infection	340
Lymphogranuloma Venereum: Genital, Inguinal, or Anorectal	342
Nongonococcal Urethritis (NGU)	342
Prevention of Ophthalmia Neonatorum	343
Parasitic Skin Infections	343
Acute Pelvic Inflammatory Disease (PID): Endometritis, Salpingitis, Parametritis, and/or Peritonitis	345
Syphilis	347
Trichomoniasis	352
Genital and Anal Warts (Condylomata Acuminata)	353
Other Genitourinary Syndromes in Men	355
Other Genitourinary Syndromes in Women	356
Prevention of Special Maternal and Neonatal Infections	358
Special Treatment-Related Discussions	359
Index	363

Section I

ANTIBIOTICS

The summaries of antibiotics that follow are designed to provide the clinician with an overview of the clinical use of each agent, along with pertinent facts concerning comparative efficacy and toxicity, if similar agents are available. Each section provides information on appropriate dosage and administration in patients with normal and impaired renal function and other important clinical pharmacologic parameters. Sections on adverse reactions and significant drug interactions are provided, and a few references are listed to allow the reader to review each agent in more depth or to investigate more controversial points.

An attempt is made to provide information on all currently useful antibiotics. Older drugs that have fallen into relative disuse are not included. For example, semisynthetic penicillins such as phenethicillin or hetacillin, cephalosporins such as cephaloridine or cephaloglycin, aminoglycosides such as neomycin, or agents such as triacetyloleandomycin have little to no role in current clinical medicine and are either less effective or more toxic than new agents. Our experience and other clinical data document the relative lack of interstitial nephritis secondary to nafcillin. Since methicillin is associated with a significant incidence of nephritis, and since oxacillin may be hepatotoxic, recommendations in the manual are for the use of nafcillin in the treatment of staphylococcal infection. Over the past 5 years there have been an increasing number of reports of infections with methicillin (or nafcillin)-resistant *Staphylococcus aureus* in US hospitals. In some medical centers, 20 to 50% of all *S. aureus* isolates and up to two-thirds of *S. epidermidis* isolates are resistant to methicillin. In these settings, vancomycin is the empiric treatment of choice for serious staphylococcal infections. Although methicillin-resistant *S. aureus* isolates may appear to be sensitive to other agents by routine disc testing, these antibiotics (e.g., cephalosporins) are either ineffective or unproven in methicillin-resistant *S. aureus* infection.

Several tetracycline and sulfonamide derivatives are deliberately ex-

cluded, since these analogs offer no advantage over tetracycline or sulfisoxazole in the treatment of infectious diseases. Exceptions are noted in the summaries of each drug. It must be emphasized that although the summaries reflect the majority of opinions on clinical use, they also contain our opinions and interpretation of the available data, as well as our experiences.

Several "third-generation" cephalosporins and "fourth-generation" penicillins have become available for clinical use, and these are included in the summaries. Cinoxacin (a nalidixic-acid analog), acyclovir, ketoconazole, and netilmicin are included as well. Data are also supplied on agents which are investigational at the time of this writing, but which we expect to soon be available.

DEFINITIONS

Serum Concentrations. The values provided are the expected maximal concentrations achieved after administration of the listed dose.

Urinary Concentrations. The values provided are the range of maximal concentrations achievable after administration of the listed dose in a patient with normal renal function.

Volume of Distribution (V_D). The apparent volume of distribution is that volume of fluid into which the drug appears to distribute through body fluid compartments and by its uptake into tissues. It is a relationship between the total amount of drug in the body and the serum concentration $\left(\frac{\text{Amount of drug in the body}}{\text{Serum concentration}} = V_D \right)$, and is expressed as volume (L) or volume per unit weight (L/kg).

Half-Life ($t_{1/2}$). When absorption and distribution are complete, the plasma concentrations for most antibiotics decline exponentially; thus drug elimination follows first-order kinetics. The slope of the curve obtained during this phase is equal to the elimination rate constant (k). Half-life is related to the slope k by the equation:

$$t_{1/2} = \frac{\ln 2}{k} = \frac{0.693}{k}$$

The slope of the curve and half-life can be estimated by a plot of drug concentration (log scale) versus time (linear scale) (see Fig. 1-1).

PROTEIN BINDING

The values listed are the average reported for percent of drug bound to plasma proteins. These data are potentially important since highly protein bound drugs are generally not cleared by hemodialysis. Additionally, the protein-bound drug is not antibacterially active and the bound drug is not diffusible.




Fig. 1-1. In order to estimate the half-life of a drug, one should (1) draw a straight line connecting the two measured plasma levels at the appropriate time; and then (2) choose two points along the line, the first of which is half the concentration of the second. The time it takes for the C_p to decline by half (8 to 4 mcg/ml) is $5\frac{1}{2}$ hours.

PERCENT OF DRUG EXCRETED UNCHANGED

The fraction of a dose of an antibiotic that is eliminated in the unchanged (nonmetabolized) form by the kidneys is reflected in the percent of drug excreted unchanged. This value is important for two reasons: Drugs that are minimally removed by urinary excretion may not be effective in the treatment of urinary tract infection, particularly in patients with reduced renal function; and drugs which are predominantly eliminated unchanged will generally require dosage adjustment in renal failure. The extent of this adjustment depends on several factors, including the extent of renal elimination (the half-life of a drug which is 50% excreted unchanged will double in anuria, whereas the half-life of aminoglycosides [95% excreted unchanged] will increase twentyfold), and the toxicity of the compound. For example, although ampicillin accumulates to a significant extent in renal failure, it is relatively nontoxic and dosage adjustment need not be as rigorous as for aminoglycosides.

ESTIMATING RENAL FUNCTION

Creatinine clearance is the most frequently used measure of renal function. The clearances of most antibiotics have been correlated to creatinine clearance. Thus, it is important to be able to estimate an individual patient's endogenous renal function. This estimation is the first step in the approach to modifying a dosage regimen in renal failure. The most reliable method for estimating creatinine clearance (CL_{CR}) in adults is by the following equation developed by Cockcroft and Gault:

$$CL_{CR} = \frac{(140 - \text{Age}) (\text{Wgt in kg})}{(72) (Cr_s)} \left[\times 0.85 \text{ for women} \right]$$

Various methods are available for this estimation in infants and young children, but the most useful equation is:

$$CL_{CR} = \frac{(0.48) \text{ Hgt(cm)}}{Cr_s}$$

The equation for adults should be used with lean (ideal) body weight in kilograms. The estimate may be erroneous in patients who are malnourished or cachectic, in those with changing renal function, or in the elderly. Height is expressed in centimeters for the pediatric equation.

TESTING FOR SYNERGY

Various methods are used for in-vitro testing of synergy. The most commonly used technique involves testing a combination of antibiotics